98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40620-023-01836-0 | DOI Listing |
Ann Med Surg (Lond)
September 2025
Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.
Anemia, characterized by a decline in hematocrit (Hct) levels, is a common and significant complication in cervical cancer. It often results from tumor-induced blood loss, chemotherapy, and inflammation. This review explores the clinical implications of anemia and Hct decline in cervical cancer, emphasizing their role in prognosis and treatment.
View Article and Find Full Text PDFLife (Basel)
August 2025
Research Center for Molecular Genetics, Institute for Promotion of Medical Science Research, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.
Heme, an essential prosthetic group involved in mitochondrial respiration and transcriptional regulation, is synthesized via the rate-limiting enzyme 5-aminolevulinic acid synthase (ALAS). Utilizing heterozygous mouse models for ALAS1 and ALAS2, our studies have revealed diverse systemic consequences of chronic heme deficiency. ALAS1-heterozygous (ALAS1+/-) mice develop metabolic dysfunction characterized by insulin resistance, glucose intolerance, and abnormal glycogen accumulation, linked mechanistically to reduced AMP-activated protein kinase (AMPK) signaling.
View Article and Find Full Text PDFDrug Chem Toxicol
August 2025
Operational Research Centre in Healthcare, Near East University, Nicosia, Cyprus.
This study evaluates the phytochemical composition, antimicrobial activity, cytotoxicity, antioxidant potential, and toxicity profile of (lemongrass) leaf extract. The extract demonstrated antimicrobial activity with inhibition zones ranging from 14.33 ± 0.
View Article and Find Full Text PDFActa Histochem
August 2025
Department of Radiation Oncology; Cancer Institute, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China. Electronic address:
Blood transfusions play a critical role in breast cancer management, particularly in addressing perioperative blood loss and chemotherapy-induced anemia. However, emerging evidence suggests that transfusions may adversely affect oncologic outcomes by inducing transfusion-related immunomodulation (TRIM) and altering the tumor microenvironment (TME). TRIM suppresses cytotoxic immune responses, potentially facilitating tumor progression-especially in aggressive subtypes such as triple-negative breast cancer (TNBC) and HER2-positive cancers.
View Article and Find Full Text PDFJCO Oncol Pract
August 2025
Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases that are prognostically stratified into lower-risk (LR-MDS) and higher-risk MDS on the basis of the International Prognostic Scoring System (eg, IPSS, revised IPSS, and molecular IPSS). Anemia is a hallmark of MDS and can lead to worsening of preexisting comorbidities, long-term RBC transfusion dependence, and profound fatigue. Although RBC transfusion support provides rapid relief of anemia-associated symptoms, it also carries a risk of iron overload and alloimmunization, and is associated with a decreased quality of life.
View Article and Find Full Text PDF